Drug Type Therapeutic radiopharmaceuticals |
Synonyms 177Lu-EBTATE, No-carrier-added lutetium-177 |
Target |
Mechanism SSTR2 modulators(Somatostatin receptor 2 modulators), Ionising radiation emitters |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Thyroid Cancer, Hurthle Cell | Phase 2 | US | 08 Dec 2022 | |
Nasopharyngeal Carcinoma | Phase 1 | DE | 30 Jan 2022 | |
Neuroendocrine Tumors | Phase 1 | DE | 30 Jan 2022 |